We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Rhythm Pharmaceuticals Inc (RYTM) USD0.001

Sell:$8.83 Buy:$8.84 Change: $0.37 (4.02%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.37 (4.02%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.37 (4.02%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). Its lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. It is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. It targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.

Contact details

222 Berkeley St Fl 12
United States
+1 (857) 2644280

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$433.31 million
Shares in issue:
50.27 million
United States
US dollar

Key personnel

  • David Meeker
    Chairman of the Board, President, Chief Executive Officer
  • Hunter Smith
    Chief Financial Officer, Treasurer, Secretary
  • Pamela Cramer
    Chief Human Resource Officer
  • Jennifer Chien
    Executive Vice President, Head of North America
  • Yann Mazabraud
    Executive Vice President, Head of International
  • William Roberts
    Chief Accounting Officer
  • Linda Manning
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.